MorphoSys to Host Conference Call on Announcement Regarding the Termination of the Co-development and Co-promotion Agreement for MOR202


MARTINSRIED / MUNICH, Germany, March 27, 2015 (GLOBE NEWSWIRE) -- On 26 March 2015, MorphoSys announced that it has regained rights to MOR202 from Celgene Corporation. The companies have mutually agreed to terminate their co-development and co-promotion agreement for MOR202. Clinical development of MOR202, which currently involves a MorphoSys-sponsored phase 1/2a trial in relapsed or refractory multiple myeloma patients, will continue as planned.

Today, 27 March 2015, at 1:00 p.m. CET (8:00am EDT, 12:00pm GMT), the Management Board of MorphoSys AG will host a public conference call to discuss the announcement.

Dial-in number for the Conference Call (listen-only):

Germany:                   +49 (0) 89 2444 32975

For U.K. residents:     +44 (0) 20 3003 2666

For U.S. residents:     +1 202 204 1514

A manuscript of the conference will be available on www.morphosys.com/conference-calls in due course.

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 90 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.

 

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.

Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

 

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

 

 

 

For more information, please contact:

MorphoSys AG

Dr. Claudia Gutjahr-Löser

Head of Corporate Communications & IR

 

Mario Brkulj

Associate Director Corporate Communications & IR

 

Alexandra Goller

Manager Corporate Communications & IR

Jessica Rush

Manager Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404

investors@morphosys.com

 

Conference Announcement (PDF) http://hugin.info/130295/R/1906763/679002.pdf

HUG#1906763